STOCK TITAN

Inogen Inc - INGN STOCK NEWS

Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.

Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.

Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.

The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.

Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.

Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.

Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) announced preliminary Q4 2021 revenue between $75.9 million and $76.9 million, a 2.6% to 3.9% increase from Q4 2020. Full-year revenue for 2021 is expected to be between $357.5 million and $358.5 million, marking a 15.9% to 16.2% increase year-over-year. The revenue growth was supported by higher average selling prices and demand, despite challenges from semiconductor supply constraints. Inogen faces a potential halt in EU sales due to regulatory changes expected by May 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
none
-
Rhea-AI Summary

Gelesis has appointed Ali Bauerlein to its Board of Directors as it prepares for a public listing. Bauerlein, with a successful track record in scaling companies, previously co-founded Inogen (NASDAQ: INGN) and led it to over $300M in revenue. Gelesis aims to expand the commercialization of its product Plenity, a weight management solution. The company is also moving forward with its merger with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR), with the registration statement approved by the SEC. The combined entity's shares will trade under the ticker GLS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
management
-
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) announced the election of Elizabeth Mora as Board Chairperson, succeeding Heath Lukatch, who will remain on the Board. Ray Huggenberger is retiring from the Board after serving since 2008 but will transition to an advisory role. Mora, who joined the Board in May 2021, will also chair the Compliance Committee. The Board has been reduced to seven members. Leadership changes aim to enhance Inogen's strategic goals in respiratory care. Future performance remains uncertain due to market risks and competition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
management
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) announced that its presentation at the 40th Annual J.P. Morgan Healthcare Conference has been rescheduled to a virtual format. President and CEO Nabil Shabshab will present on January 12, 2022, at 10:30 a.m. ET. Interested investors can access the live audio webcast through the Investor Relations section on the Inogen website. A replay will be available shortly after the live event for 90 days. Inogen specializes in developing and marketing portable oxygen concentrators for patients with chronic respiratory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN), a medical technology firm specializing in respiratory products, announced participation in the 40th Annual J.P. Morgan Healthcare Conference. President and CEO Nabil Shabshab is set to present on January 12, 2022, at 10:30 a.m. PT. The live audio webcast will be accessible via the Investor Relations section of Inogen's website. A replay will be available for 90 days post-event. Inogen continues to utilize its Investor Relations platform for disclosing material non-public information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
News
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) has appointed Mike Sergesketter as Interim Chief Financial Officer, effective immediately. He succeeds Alison Bauerlein, who will remain in a transitional role until the end of Q1 2022. Sergesketter brings over 40 years of finance experience, having previously served as CFO at Kimball Electronics, where he facilitated globalization strategies. Nabil Shabshab, CEO of Inogen, expressed confidence in Sergesketter’s ability to support the company's strategic evolution in respiratory care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
Rhea-AI Summary

Inogen, Inc. (NASDAQ: INGN) reported a strong Q3 2021 performance with total revenue reaching $93.1 million, a 25.3% increase year-over-year. The domestic direct-to-consumer segment generated $36.3 million, up 24.6%, while rental revenue surged 61.3% to $12.1 million. Despite supply chain challenges, operating income was $6.4 million, and net income stood at $12.2 million, with an EPS of $0.53. However, full-year 2021 guidance remains uncertain due to ongoing semiconductor shortages affecting production and costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
-
Rhea-AI Summary

Inogen, a leader in medical technology specializing in respiratory products, announced management participation in the Stifel Virtual Healthcare Conference on November 17, 2021, at 3:20 p.m. ET. The presentation will be led by President and CEO Nabil Shabshab and CFO Alison Bauerlein. Interested stakeholders can access the webcast through the Inogen Investor Relations page, with a replay available for 90 days post-event. Inogen focuses on developing portable oxygen concentrators to support patients with chronic respiratory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
Rhea-AI Summary

Limoneira Company (NASDAQ: LMNR) announced the appointment of Elizabeth (Beth) Mora to its Board of Directors, expanding the board to 11 members, nine of whom are independent. Mora brings over 30 years of experience in finance and ESG, having held executive roles at Draper and Harvard. Her expertise is expected to enhance Limoneira's strategic direction and commitment to diversity and sustainability. Mora expressed enthusiasm for contributing to the company's long-term growth while honoring its legacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
management
Rhea-AI Summary

Inogen, Inc (NASDAQ: INGN) will announce its third quarter 2021 financial results on Thursday, November 4, 2021, after market close. The company will host a conference call at 2:00 PM PT / 5:00 PM ET for discussion. Interested parties can join by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay of the call will be available from November 4, 2021, at 4:00 PM PT until November 18, 2021, at 4:00 PM PT. Inogen provides innovative respiratory products for homecare, focusing on portable oxygen concentrators.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags

FAQ

What is the current stock price of Inogen (INGN)?

The current stock price of Inogen (INGN) is $8.48 as of December 20, 2024.

What is the market cap of Inogen (INGN)?

The market cap of Inogen (INGN) is approximately 197.9M.

What does Inogen Inc. do?

Inogen Inc. develops and manufactures portable oxygen concentrators to deliver oxygen therapy for patients with chronic respiratory conditions.

What is Inogen's flagship product?

Inogen's flagship product is the Inogen One system, a compact and lightweight portable oxygen concentrator.

How does Inogen sell its products?

Inogen sells its products through home medical equipment providers, distributors, large gas companies, and home oxygen providers. They also rent products directly to patients.

Where does Inogen generate most of its revenue?

Inogen generates the majority of its revenue in the United States.

How many patients use oxygen therapy according to Inogen?

Inogen estimates that more than 2.5 million patients in the United States and over 4.5 million patients worldwide use oxygen therapy.

What makes Inogen's products stand out?

Inogen's products, like the Inogen One system, are designed to be compact, lightweight, and travel-approved, freeing patients from heavy tanks and stationary systems.

What is the mission of Inogen Inc.?

Inogen's mission is to improve the quality of life for supplemental oxygen users by providing innovative and user-friendly oxygen therapy solutions.

Who inspired the founding of Inogen?

Inogen was inspired by Mae, the grandmother of one of the founders, who was prescribed oxygen therapy and needed a more convenient solution.

Where can I learn more about Inogen's history?

You can learn more about Inogen's history and inspiration behind its founding on their website at http://www.inogen.com/about-inogen/meet-mae/.

What is Inogen Inc.'s stock symbol?

Inogen Inc. is publicly traded with the stock symbol INGN.

Inogen Inc

Nasdaq:INGN

INGN Rankings

INGN Stock Data

197.93M
23.36M
1.84%
89.67%
3.13%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
GOLETA